香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 於2025年4月25日，本次收購已完成交割，交割後上海和黃各股東持股情況的詳情載列如下。 上海和黃由本公司直接及間接持有60%股權，成為本公司的非全資附屬公司，且其財務業績 合併計入本集團綜合財務報表內。 | 序號 | 股東名稱 | 認繳出資額 | 實繳出資額 | 持股比例 | | --- | --- | --- | --- | --- | | | | (人民幣/萬元) | (人民幣/萬元) | (%) | | 1. | 和黃投資 | 1,145 | 1,145 | 5.0000% | | 2. | 上藥藥材 | 11,450 | 11,450 | 50.0000% | | 3. | 本公司 | 2,290 | 2, ...

上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） | 關於本報告 | 001 | | --- | --- | | 董事長致辭 | 003 | | 走進上海醫藥 | 005 | | 年度專題： | 013 | 科技引領醫療創新 攜手共繪健康藍圖 | 可持續發展治理體系 | 021 | | --- | --- | | 可持續發展治理模型 | 023 | | 利益相關方識別與溝通 | 026 | | 雙重重要性分析 | 027 | | 響應聯合國可持續發展目標（SDGs） | 029 | | 守正篤行， 同德共鑄發展根基 | 031 | | 黨建引領發展 | 033 | | --- | --- | | 穩健公司治理 | 034 | | 堅持合規運營 | 039 | | 深化數字化運營 | 049 | | 向新而行， | 051 | | --- | --- | | 同力共築健康中國 | | | 創新驅動發展 | 053 | | 提升健康可及 | 057 | | 卓越品質保障 | 064 ...

Financial Performance - Shanghai Pharmaceuticals Group reported a revenue increase of 12% year-on-year for the fiscal year 2024, reaching RMB 50 billion[3]. - The company achieved a net profit of RMB 5 billion, representing a growth of 15% compared to the previous year[3]. - Revenue for 2023 reached RMB 260.30 billion, an increase of 12.2% compared to 2022[17]. - Pre-tax profit for 2023 was RMB 7.05 billion, a decrease of 20% from 2022[17]. - The company achieved a net profit of RMB 5.17 billion for 2023, down 26.2% from the previous year[17]. - In 2024, the company achieved operating revenue of RMB 275.25 billion, a year-on-year increase of 5.75%[25]. - The net profit attributable to shareholders reached RMB 4.55 billion, up 20.82% year-on-year[26]. - The pharmaceutical industrial segment reported sales revenue of RMB 23.73 billion, a decline of 9.62% year-on-year, while the pharmaceutical commercial segment saw sales revenue of RMB 251.52 billion, an increase of 7.47%[25]. - The company reported a net operating cash flow of RMB 5.83 billion, an increase of 11.39% year-on-year, indicating high-quality development[28]. - The company's operating revenue for the reporting period reached ¥275.25 billion, an increase of 5.75% compared to ¥260.30 billion in the same period last year[55]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[3]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[7]. - The company has completed its first-year sales targets in Thailand and initiated operations in the Philippines and the UAE, marking significant international expansion[43]. - The company aims to leverage Hong Kong as a strategic hub to promote traditional Chinese medicine globally, aligning with national development strategies[43]. - The company is exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[198]. Research and Development - Shanghai Pharmaceuticals is investing RMB 1 billion in new product development, focusing on innovative drug formulations[3]. - The company plans to enhance its innovative drug pipeline, with one new drug approved for market and several others advancing in clinical stages[21]. - Research and development investment totaled RMB 2.82 billion, with R&D expenses of RMB 2.39 billion, reflecting an 8.64% year-on-year growth[27]. - The company has established partnerships with top universities to promote innovation in drug development[20]. - The company aims to enhance existing products and potential products through marketing reforms, technology upgrades, and supply chain optimization[33]. - The company is focusing on both new product launches and existing product approvals to drive growth[71]. - The company is committed to continuous innovation and development in its pharmaceutical offerings[71]. Digital Transformation and Technology - Shanghai Pharmaceuticals aims to enhance its digital health services, with a projected investment of RMB 500 million over the next two years[3]. - The digital transformation initiatives have led to the recognition of the company’s smart factory as a national excellence-level facility[21]. - The company is leveraging digital technologies to improve customer engagement and streamline operations[200]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30%[8]. Sustainability and Corporate Responsibility - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 20% by 2025[3]. - The company’s environmental policies and performance are detailed in its 2024 Corporate Social Responsibility Report[158]. - The company disclosed its charitable contributions in the 2024 Sustainable Development Report and ESG Report[97]. Human Resources and Management - The company employed a total of 49,402 staff, with 19,370 in sales and 15,152 in production roles[170]. - The company has a total of 180 employees with doctoral degrees and 2,336 with master's degrees[170]. - The company has implemented a comprehensive training program for new employees, achieving full coverage with over 2,700 participants in 2024[175]. - The company has established a differentiated compensation system for various roles, including management, marketing, R&D, and production personnel, to align with performance and market conditions[171]. Financial Guidance and Future Outlook - The company has set a performance guidance of 10-15% revenue growth for the next fiscal year[3]. - The company provided guidance for the next quarter, expecting revenue to be between $1.3 billion and $1.4 billion, indicating a growth rate of 10% to 15%[3]. - Future outlook includes a commitment to research and development of new drugs and technologies to meet evolving healthcare needs[200]. - Overall, the management remains optimistic about achieving long-term growth targets despite market challenges[199].

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於鹽酸纈更昔洛韋片獲得美國 FDA 批准文號的公告》、 《上海醫藥集團股份有限公司關於召開 2025 年第一季度業績說明會的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 中國上海，2025 年 4 月 23 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生 ...

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司 ） （股份代碼：02607） 關連交易 擬參與設立生物醫藥併購基金 最新進展 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年1月28日的公告（「該公 告」），內容有關，本公司擬參與設立生物醫藥併購基金。除另有界定外，本公告所 用詞彙與該公告所界定者具有相同涵義。 訂立合夥協議及完成工商設立手續 董事會欣然宣佈，於2025年3月26日，本公司與國投先導（作為有限合夥人）、東富龍 （作為有限合夥人）、君實生物（作為有限合夥人）、鎂信健康（作為有限合夥人）、 浦東引領區基金（作為有限合夥人）、張江科技（作為有限合夥人）、興嘉二期（作 為有限合夥人）、馬陸發展（作為有限合夥人）、新華保險（作為有限合夥人）、中 贏創新（作為有限合夥人）、上實資本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 董事會會議通告 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年四月十四日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先 生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、 王忠先生及萬鈞女士。 * 僅供識別 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年四月二十八日（星期一）舉行，藉以（其中包括） 批准本公司及其附屬公司截至二零二五年三月三十一日止三個月之第一季度業 績及其發佈。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十一次會議決議公告》、《上海醫藥集 團股份有限公司關於高級管理人員變動的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 9 日 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 1、《关于聘任公司高级管理人员的议案》 同意聘任周亚栋女士担任公司副总裁兼财务总监，任期至第八届董事会届满 时止。同时沈波先生不再担任公司财务总监职务。 证券代码：6016 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 证券代码：601607 证券简称：上海医药 公告编号：临2025-044 上海医药集团股份有限公司 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於入選全球最具價值醫藥品牌 25 強的自願性公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 4 月 8 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非 ...

Market News - The National Bureau of Statistics will release March CPI and PPI data on April 10, with February figures showing a month-on-month CPI decrease of 0.2% and a year-on-year decrease of 0.7%, while PPI decreased by 0.1% month-on-month and 2.2% year-on-year [2] - The People's Bank of China has 763.4 billion yuan in reverse repos and 150 billion yuan in treasury cash deposits maturing this week, with specific amounts maturing each day [3] - The U.S. will release March CPI data on April 10, which is expected to be a significant test for the dollar, as persistent inflation could support the dollar and raise concerns about further interest rate cuts by the Federal Reserve [4] Sector Events - The 10th China Science and Technology Finance Forum will be held in Beijing on April 7, focusing on summarizing reform achievements and innovative paths for the future of technology finance [6] - The 2025 Global 6G Technology and Industry Ecosystem Conference will take place in Nanjing from April 10 to 12, gathering global leaders in the 6G field to discuss innovation and future industry development [7] - The Ministry of Commerce has announced export controls on seven categories of medium and heavy rare earths, effective immediately, to safeguard national security and fulfill international obligations [8] - Amazon plans to launch its first batch of 27 satellites for its Project Kuiper on April 9, entering competition with SpaceX's Starlink [9] Company News - HeXin Instruments plans to acquire a 56% stake in Shanghai Liangxi Technology Co., Ltd. through a combination of share issuance and cash payment [11] - Shengnong Development intends to acquire a 54% stake in Anhui Sun Valley Food Technology Group for 1.126 billion yuan, enhancing its integrated industry chain [12] - Lier Chemical expects a net profit of 145 to 155 million yuan for Q1 2025, representing a year-on-year increase of 203.08% to 223.98% due to rising sales and prices [13] - Stone Technology reported a revenue of 11.945 billion yuan for 2024, a year-on-year increase of 38.03%, and a net profit of 1.977 billion yuan, a decrease of 3.64% [14] - Chengdi Xiangjiang announced a contract worth 4.452 billion yuan for a data center project with China Mobile, with a cooperation period of seven years plus an uncertain duration [15] Restricted Shares - This week, 24 companies in the A-share market will have a total of 1.735 billion shares released from restrictions, with a total market value of 35.015 billion yuan, an increase of 12.411 billion yuan week-on-week [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total of approximately 42.6 million shares and expected fundraising of 1.161 billion yuan [21] Market Outlook - Dongfang Securities suggests the market may see a turning point post-holiday, with potential for a rebound as policy benefits are released in Q2 [24] - Founder Securities believes A-shares may perform better than global markets due to positive macro policies and recovering domestic demand [25] - Dongguan Securities anticipates a range-bound market in the short term due to global volatility and upcoming earnings reports [26] - Guojin Securities recommends a shift in investment strategy towards large-cap value stocks, focusing on "profit bottom" logic in the upcoming quarter [27]